Two Sigma Advisers LP raised its position in Veracyte Inc (NASDAQ:VCYT) by 61.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 119,600 shares of the biotechnology company’s stock after buying an additional 45,500 shares during the period. Two Sigma Advisers LP owned about 0.30% of Veracyte worth $1,505,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of VCYT. Assenagon Asset Management S.A. acquired a new stake in Veracyte in the 4th quarter worth about $15,299,000. BlackRock Inc. boosted its holdings in Veracyte by 43.6% in the 3rd quarter. BlackRock Inc. now owns 2,998,763 shares of the biotechnology company’s stock worth $28,638,000 after buying an additional 910,427 shares during the last quarter. Allianz Asset Management GmbH boosted its holdings in Veracyte by 233.9% in the 3rd quarter. Allianz Asset Management GmbH now owns 637,846 shares of the biotechnology company’s stock worth $6,091,000 after buying an additional 446,817 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Veracyte by 86.1% in the 3rd quarter. Renaissance Technologies LLC now owns 940,400 shares of the biotechnology company’s stock worth $8,981,000 after buying an additional 435,000 shares during the last quarter. Finally, Vanguard Group Inc boosted its holdings in Veracyte by 40.0% in the 3rd quarter. Vanguard Group Inc now owns 1,434,497 shares of the biotechnology company’s stock worth $13,700,000 after buying an additional 409,641 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.
VCYT opened at $25.49 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 7.16 and a current ratio of 7.42. Veracyte Inc has a 1-year low of $5.39 and a 1-year high of $26.75. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -41.11 and a beta of 1.03.
Several equities research analysts recently issued reports on VCYT shares. BTIG Research lifted their price objective on Veracyte to $17.00 and gave the stock a “buy” rating in a report on Friday, January 4th. BidaskClub upgraded Veracyte from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 22nd. Finally, Zacks Investment Research cut Veracyte from a “buy” rating to a “hold” rating in a report on Tuesday, February 19th. Two analysts have rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $15.83.
COPYRIGHT VIOLATION NOTICE: “Veracyte Inc (VCYT) Shares Bought by Two Sigma Advisers LP” was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2019/04/11/veracyte-inc-vcyt-shares-bought-by-two-sigma-advisers-lp.html.
Veracyte Company Profile
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
Recommended Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.